Once in a while, it’s fun to get creative about something you feel passionate about, and that’s how this “fairy tale” came to be. Over the course of the first three installments, the big and powerful B-Techs became frustrated when the New Innovators threatened their dominance, so they hatched a pernicious plan to bring down the pesky patentees.
Recent Posts
Behemoth-Tech and the Little Innovators — The Story Unfolds
Part II of A Four-Part Tale: The Path of Innovation Leads to Competition
So, yes: I wrote “a fairy tale.” Well, sort of. As I noted in the “first installment” on Monday, a bunch of things came together all at once—including a Sunday morning when I had a little extra time. So I cued up this story of how the Behemoth Tech companies became big and powerful because of their imaginative use of chips. But as time passes, innovation can be hard to replicate.
Behemoth-Tech and the Little Innovators
A Fairy Tale That’s All Too True (For Aren’t They All?) — and Patently Allegorical
“A fairy tale?” you ask. Well, yes. Because every once in a while, even though the work has piled up, you feel energized and spirited about something enough during breakfast on a Sunday morning that ideas just well up and the words spring onto the page. And if you have a couple of spritely, cheerful teenage daughters who occasionally read stories, narratives intersect and you just have a little fun with things. And that’s what happened here. So, a fairy tale … of a sort. And here goes.
Doomsday for Patents? Readers Agree.
Readers React to Post on IPWatchdog; Patents In “A Sad State of Affairs”
In posts here on my blog on March 27 and April 3, I described how in Evolutionary Intelligence v. Sprint et al. the district court for the Northern District of California invalidated a valuable pair of what had been durable software patents—a decision that in February the Federal Circuit upheld.
Both courts erred in overlooking valid claims, although in the wake of the wacky Alice ruling, such a decision might not have been unexpected.
One Way to Make America Great Again? Protect Patented Innovation!
I have a hard time listening to Washington politicians these days. All I hear is obfuscation and finger-pointing. Nothing seems to get done. And while the finger-pointing seems worse than ever, the inability to get anything done is par for the course.
If neither Congress nor the President can provide results, how can we get this country back on track?
Evolutionary Intelligence Requests Amicus Support on Petition for Rehearing
Please consider the below amicus request for support overturning an important section 101 decision at the Federal Circuit and thereby providing consistent guidance on what types of inventions are “abstract.”
Evolutionary Intelligence will be filing a combined petition for rehearing and rehearing en banc at the Federal Circuit on April 19, 2017. Amicus support would be due by May 3, 2017.
TDR Files SCOTUS Amicus Brief for AIPLA in TC Heartland
Addressing Venue in Patent Cases
I am honored to have drafted the brief on behalf of the American Intellectual Property Law Association (AIPLA) in TC Heartland LLC v Kraft Food Group Brands LLC, U.S., No. 16-341 (2017), which concerns the appropriate scope of venue in patent infringement cases.
The brief supports the Federal Circuit interpretation of the general venue statute at 28 U.S.C. 1391 as providing a definition of “resides” applicable in the patent venue statute later in that chapter at 28 U.S.C. 1400(b).
Tabet DiVito & Rothstein: Why I Made the Leap
As the Law Firm Model Evolves, So Must Attorneys
Monday, May 2, was a big day for me: I joined specialist litigation firm Tabet DiVito & Rothstein LLC as a partner.
There’s a story here, of course. Katten is a great firm with great people. I learned a lot while I was there. But I’ve worked my entire career at some pretty large law firms, and while I appreciated the opportunities, experience, and advantages that big law presents, it was time for a change.
Economics of Biosimilars: Zarxio Debut Sparks Debate.
Will BPCIA Affect Innovators’ Plans for Developing New Biologics?
Here come the biosimilars. Last month, Sandoz, a subsidiary of Swiss multinational pharmaceutical company Novartis, launched Zarxio, the first U.S.-approved biosimilar to be introduced under the Biologics Price Competition and Innovation Act.
BPCIA, as the reader likely knows, created a pathway to regulatory approval of a competitive biologic, analogous to what Hatch-Waxman did with the accelerated new drug application (ANDA) route for generic pharmaceuticals in 1984.
Warning! Patents Disrupt Safety of Thousands! (Not Really.)
Or, How Hyperbolic Headlines and Biased Reporting Affect Patent Reform
Breaking news! Did you hear? “Patent troll disrupts safety of thousands; victims urge Congress to legislate.” So runs the headline from a recent article by reporter Amanda Ciccatelli at InsideCounsel.com.
Stop the presses!!! One patent troll is disrupting the safety of thousands, and its victims are urging Congress to legislate. Help!